NASDAQ:QNTM Quantum Biopharma (QNTM) Stock Price, News & Analysis $2.90 +0.03 (+1.05%) Closing price 08/5/2026 04:00 PM EasternExtended Trading$2.84 -0.06 (-2.07%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock About Quantum Biopharma Stock (NASDAQ:QNTM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Quantum Biopharma alerts:Sign Up Key Stats Today's Range$2.77▼$3.0050-Day Range$2.83▼$7.0252-Week Range$2.07▼$31.91Volume91,156 shsAverage Volume88,785 shsMarket Capitalization$18.56 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada. Read More Quantum Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks14th Percentile Overall ScoreQNTM MarketRank™: Quantum Biopharma scored higher than 14% of companies evaluated by MarketBeat, and ranked 842nd out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingQuantum Biopharma has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageQuantum Biopharma has only been the subject of 1 research reports in the past 90 days.Read more about Quantum Biopharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Quantum Biopharma is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Quantum Biopharma is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioQuantum Biopharma has a P/B Ratio of 2.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Quantum Biopharma's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.79% of the float of Quantum Biopharma has been sold short.Short Interest Ratio / Days to CoverQuantum Biopharma has a short interest ratio ("days to cover") of 3.77, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Quantum Biopharma has recently decreased by 5.35%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldQuantum Biopharma does not currently pay a dividend.Dividend GrowthQuantum Biopharma does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.68 News SentimentQuantum Biopharma has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Quantum Biopharma this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for QNTM on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows10 people have added Quantum Biopharma to their MarketBeat watchlist in the last 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Quantum Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders8.53% of the stock of Quantum Biopharma is held by insiders.Percentage Held by Institutions1.24% of the stock of Quantum Biopharma is held by institutions.Read more about Quantum Biopharma's insider trading history. Receive QNTM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Quantum Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. QNTM Stock News HeadlinesQuantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances MS Imaging Study with Encouraging Preliminary ResultsAugust 3 at 6:06 PM | markets.businessinsider.comQuantum BioPharma (QNTM) Advances MS Imaging Study With Encouraging Preliminary ResultsAugust 3 at 6:06 PM | finance.yahoo.comTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now. | Altimetry (Ad)Quantum Biopharma (NASDAQ:QNTM) Rating Increased to Sell at Wall Street ZenAugust 1, 2026 | americanbankingnews.comQuantum Biopharma (QNTM) to Post Earnings on ThursdayJuly 30, 2026 | americanbankingnews.comQuantum BioPharma Announces Closing of Debt SettlementJuly 29, 2026 | globenewswire.comQuantum BioPharma (QNTM) Executive Outlines Lucid-MS Development Strategy and Commercial Growth PlansJuly 29, 2026 | finance.yahoo.comQuantum BioPharma (QNTM) Developing Two-Pronged Attack on Brain Disorders Affecting MillionsJuly 22, 2026 | finance.yahoo.comSee More Headlines QNTM Stock Analysis - Frequently Asked Questions How have QNTM shares performed this year? Quantum Biopharma's stock was trading at $7.30 at the start of the year. Since then, QNTM stock has decreased by 60.3% and is now trading at $2.90. How were Quantum Biopharma's earnings last quarter? Quantum Biopharma Ltd. (NASDAQ:QNTM) announced its earnings results on Thursday, March, 26th. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.22) by $0.49. How do I buy shares of Quantum Biopharma? Shares of QNTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Quantum Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Quantum Biopharma investors own include Jiuzi (JZXN), Aethlon Medical (AEMD), Aditxt (ADTX), Adial Pharmaceuticals (ADIL), Avalon GloboCare (ALBT), Ainos (AIMD) and AMC Entertainment (AMC). Company Calendar Last Earnings3/26/2026Today8/06/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 QNTM's financial health is in the Yellow zone, according to TradeSmith. QNTM has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:QNTM Previous SymbolNASDAQ:QNTM CIK1771885 Webwww.fsdpharma.com Phone416-854-8884FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)($8.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$26.17 million Net MarginsN/A Pretax MarginN/A Return on Equity-941.54% Return on Assets-224.41% Debt Debt-to-Equity RatioN/A Current Ratio0.63 Quick Ratio0.63 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.34 per share Price / Book2.16Miscellaneous Outstanding Shares6,400,000Free Float5,853,000Market Cap$18.56 million OptionableN/A Beta0.45 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:QNTM) was last updated on 8/6/2026 by MarketBeat.com Staff. From Our PartnersThe dollar reset no one told you aboutPorter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-ye...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredControl 100 shares without spending thousands of dollarsWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredA $5 stock inside Kennedy Space Center?A small publicly traded company operates a specialized launch vehicle fleet inside the secure perimeter of Ken...Freedom Financial | SponsoredA Secret Plan to End Trump in November?A White House insider with close ties to the Trump family is speaking out about what he calls the biggest poli...Paradigm Press | SponsoredALT SL: New Patent Reveals Elon Musk’s Next Breakthrough: M.A.G.I.Jeff Brown and Marc Chaikin - two investors who spotted Nvidia a decade ago - are now pointing to Elon Musk's ...Brownstone Research | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quantum Biopharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Quantum Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
